Press Release Jun 30 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding its final approval from the USFDA for Lacosamide Injection. This injection is intended for treating partial-onset seizures and primary generalized tonic-clonic seizures. The product will be manufactured at the company's facility in Jarod, India, and has a significant market size.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jun 07 2022
- Press Release Jun 06 2022
- Press Release May 27 2022
- Press Release May 26 2022
- Press Release May 13 2022
Later from Zydus Lifesciences
- Press Release Jul 08 2022
- Press Release Jul 11 2022
- Press Release Jul 18 2022
- Press Release Jul 21 2022
- Press Release Jul 26 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences